How is Oncotype DX different from other genomic tests?
Oncotype DX is specifically designed to assess the risk of recurrence and the potential benefit of chemotherapy in certain types of cancer. Other genomic tests, such as MammaPrint or Prosigna, may focus on different sets of genes or provide additional insights, such as the risk of distant metastasis. Each test has its unique methodology and clinical applications, so the choice of test depends on the specific clinical scenario.
